[Federal Register Volume 69, Number 138 (Tuesday, July 20, 2004)]
[Notices]
[Page 43436]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-16386]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substance; Notice of Application

    Pursuant to 21 CFR 1301.33(a), this is notice that on June 7, 2004, 
Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte 
Drive, West Deptford, New Jersey 08066, made application by letter to 
the Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of Dihydromorphine (9145), a basic class of controlled 
substance listed in Schedule I.
    The company plans to manufacturer Dihydromorphine for internal use 
in production of other controlled substances for distribution to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistance Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCD) and must be filed not later than September 20, 2004.

    Dated: July 8, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-16386 Filed 7-19-04; 8:45 am]
BILLING CODE 4410-09-M